For example, bladder cancers with Fibroblast Growth Factor Receptor 3 (FGFR3) mutations have shown sensitivity to FGFR inhibitors like erdafitinib, illustrating how genetic data inform therapeutic choices [6]. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.